Frontlight ResearchEarly access
Active, not recruitingNo phase
MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms
Key facts
- Who runs it
- CooperVision, Inc.
- Where
- Athens, Beaumont, Bellevue, Birmingham, Bloomington, Boston, Chesapeake, Chicago, Columbus, Downers Grove, Edina, Fullerton, Glenview, Granville, Houston, Kansas City, Katy, La Mesa, Memphis, Miamisburg, Ocoee, Ogden, Pittsburg, Plano, Powell, Santa Ana, Schaumburg, Tamarac, and Tampa, United StatesSee the 30 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 900 people, planned
- Started
- 25 Jun 2022
- Expected to end
- 30 Jun 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MiSight 1 Day
- Proclear 1 day
- Record updated
- 8 July 2026
Who can take part
- Age
- 8 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- Informed Consent and Assent have been completed
- Be between 8 and 12 years of age inclusive at the time of enrollment
- Manifest Refraction - Spherical Equivalent Refractive Error (SERE) at baseline between -0.75 D and -4.00 D inclusive (at the corneal plane) in each eye
- Best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye
- Anisometropia: ≤ 1.50D SERE
- Astigmatism: ≤ 0.75 D
- Free of ocular disease or abnormalities (including any corneal scar)
- Currently have good general health
- Agree to accept the lens as assigned by the randomization
- Be capable of comprehending the nature of the study and be willing and able to adhere to the instructions set forth in this protocol
- Ability to comply with study procedures, including high and low (sub-study only) contrast high and low (sub-study only) lighting visual acuity, axial length, and cycloplegic auto-refraction measurements taken for both eyes
- Able to maintain the visit schedule
- Willingness to participate in the trial for 4 years
- Interested in wearing contact lenses for approximately 10 hours per day and 6 days per week
- Possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses
Who cannot take part
- Current or prior use of any pharmaceuticals or other methods for control of myopia, such as bifocals, progressive addition lenses, orthokeratology, atropine, pirenzepine or any other myopia control treatment
- Use of any systemic or topical ocular medications or over-the-counter artificial tears which might interfere with contact lens wear, pupil size, accommodation or refractive state, or require the lenses to be removed during the day
- Previously worn or currently wears rigid gas permeable contact lenses, including orthokeratology lenses
- Has any of the following specific contraindications to MiSight 1 Day lenses at Baseline Visit:; Acute and subacute inflammation or infection of the anterior chamber of the eye; Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids; Severe insufficiency of lacrimal secretion (dry eyes); Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic; Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses; Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions; Any active corneal infection (bacterial, fungal, or viral); If eyes are red or irritated; The patient is unable to follow lens handling and wear regimen or unable to obtain assistance to do so
- Has history of:; Corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections; Giant papillary conjunctivitis; Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses; A known allergy to fluorescein, benoxinate, proparacaine or tropicamide; Corneal hypoesthesia (reduced corneal sensitivity)
- Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses
- Keratoconus or an irregular cornea
- Strabismus or amblyopia
Where in United States
- Athens Eye CareAthens, United States
- Texas State OpticalBeaumont, United States
- Factoria Eye ClinicBellevue, United States
- University of Alabama School of OptometryBirmingham, United States
- Clinical Optics Research Lab at IU School of OptometryBloomington, United States
- New England College of OptometryBoston, United States
- Virginia Pediatric Eye CareChesapeake, United States
- Illinois College of OptometryChicago, United States
- SoLo Eye Care & Eyewear GalleryChicago, United States
- Ohio State UniversityColumbus, United States
- Chicago College of OptometryDowners Grove, United States
- Cornea and Contact Lens InstituteEdina, United States
- Marshall B. Ketchum University Southern California College of OptometryFullerton, United States
- Carillon Vision CareGlenview, United States
- ProCare Vision Center, Inc.Granville, United States
- University of Houston College of OptometryHouston, United States
- Vision Source EyeCareKansas City, United States
- Vision One EyecareKaty, United States
- Vision Solutions Optometry IncLa Mesa, United States
- Southern College of OptometryMemphis, United States
- Miamisburg Vision CareMiamisburg, United States
- Coan Eye Care and Optical BoutiqueOcoee, United States
- Utah Eye CentersOgden, United States
- Kannarr Eye CarePittsburg, United States
- Lone Star VisionPlano, United States
- Eye Care ProfessionalsPowell, United States
- Paje OptometricSanta Ana, United States
- Brain Vision InstituteSchaumburg, United States
- West Broward Eyecare AssociatesTamarac, United States
- Bright Eyes Family Vision CareTampa, United States
About the trial
What the trial wants to find out
The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.
The 2 groups in the trial
- MiSight 1 dayTreatment being tested
- Proclear 1 dayExisting treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 8 July 2026